Sigachi Industries aims to increase Revenue Potential by INR 250 cr Commencing from Q427
Jan 23, 2026
Hyderabad (Telangana) [India], January 23: Sigachi Industries Ltd. (NSE: SIGACHI; BSE: 543389), a leading Indian pharmaceutical company, today announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor.